Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice
Interim pharmacokinetic and safety updates continue to support the Phase 2 profile, and researchers are closely watching for the larger, longer-duration data that will ultimately shape the regulatory trajectory for the molecule
Beginning as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Lillys Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly's once-daily obesity pill, provided both receive approval from the US Food and Drug Administration (FDA), according to a news release from Lilly
Although it is vital for your health, there has been increasing discussion about whether it may also have an effect on your skin
Both are effective for weight loss, but retatrutide may offer faster results